{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,16]],"date-time":"2025-09-16T20:07:05Z","timestamp":1758053225134,"version":"3.44.0"},"reference-count":71,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinicalradiologyonline.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Radiology"],"published-print":{"date-parts":[[2022,1]]},"DOI":"10.1016\/j.crad.2021.08.001","type":"journal-article","created":{"date-parts":[[2021,9,17]],"date-time":"2021-09-17T03:27:23Z","timestamp":1631849243000},"page":"e1-e10","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Post-chemotherapy and targeted therapy imaging of the chest in lung cancer"],"prefix":"10.1016","volume":"77","author":[{"given":"B.W.","family":"Carter","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Altan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.S.","family":"Shroff","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.T.","family":"Truong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I.","family":"Vlahos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.crad.2021.08.001_bib1","doi-asserted-by":"crossref","first-page":"2542","DOI":"10.1056\/NEJMoa061884","article-title":"Paclitaxel\u2013carboplatin alone or with bevacizumab for non-small-cell lung cancer","volume":"355","author":"Sandler","year":"2006","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.crad.2021.08.001_bib2","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/s11912-019-0770-x","article-title":"Emerging targeted therapies for the treatment of non-small cell lung cancer","volume":"21","author":"Halliday","year":"2019","journal-title":"Curr Oncol Rep"},{"issue":"5","key":"10.1016\/j.crad.2021.08.001_bib3","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1097\/JTO.0b013e31824cc334","article-title":"Genetic changes in squamous cell lung cancer: a review","volume":"7","author":"Heist","year":"2012","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.crad.2021.08.001_bib4","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1056\/NEJMoa011954","article-title":"Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer","volume":"346","author":"Schiller","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.crad.2021.08.001_bib5","doi-asserted-by":"crossref","first-page":"3543","DOI":"10.1200\/JCO.2007.15.0375","article-title":"Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer","volume":"26","author":"Scagliotti","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.crad.2021.08.001_bib6","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1634\/theoncologist.2008-0232","article-title":"The differential efficacy of pemetrexed according to NSCLC histology: a review of two Phase III studies","volume":"14","author":"Scagliotti","year":"2009","journal-title":"Oncologist"},{"key":"10.1016\/j.crad.2021.08.001_bib7","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.1200\/JCO.2011.39.5848","article-title":"Weekly nab-paclitaxel in combination with carboplatin versus solvent-based paclitaxel plus carboplatin as first-line therapy in patients with advanced non-small-cell lung cancer: final results of a phase III trial","volume":"30","author":"Socinski","year":"2012","journal-title":"J Clin Oncol"},{"issue":"28","key":"10.1016\/j.crad.2021.08.001_bib8","doi-asserted-by":"crossref","first-page":"4617","DOI":"10.1200\/JCO.2008.17.7162","article-title":"Chemotherapy in addition to supportive care improves survival in advanced non-small-cell lung cancer: a systematic review and meta-analysis of individual patient data from 16 randomized controlled trials","volume":"26","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.crad.2021.08.001_bib9","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1186\/s12916-017-0819-3","article-title":"Successes and failures: what did we learn from recent first-line treatment immunotherapy trials in non-small cell lung cancer?","volume":"15","author":"Remon","year":"2017","journal-title":"BMC Med"},{"issue":"15","key":"10.1016\/j.crad.2021.08.001_bib10","doi-asserted-by":"crossref","first-page":"2121","DOI":"10.1200\/JCO.2010.31.8923","article-title":"American Society of Clinical Oncology provisional clinical opinion: epidermal growth factor receptor (EGFR) Mutation testing for patients with advanced non-small-cell lung cancer considering first-line EGFR tyrosine kinase inhibitor therapy","volume":"29","author":"Keedy","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.crad.2021.08.001_bib11","doi-asserted-by":"crossref","first-page":"188","DOI":"10.2174\/138161209787002915","article-title":"Targeted therapies in lung cancer","volume":"15","author":"Pirker","year":"2009","journal-title":"Curr Pharm Des"},{"issue":"25","key":"10.1016\/j.crad.2021.08.001_bib12","doi-asserted-by":"crossref","first-page":"2983","DOI":"10.2217\/fon-2019-0400","article-title":"Optimizing outcomes and treatment sequences in EGFR mutation-positive non-small-cell lung cancer: recent updates","volume":"15","author":"Girard","year":"2019","journal-title":"Future Oncol"},{"key":"10.1016\/j.crad.2021.08.001_bib13","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.2147\/OTT.S66502","article-title":"Tumour heterogeneity and resistance to EGFR-targeted therapy in advanced nonsmall cell lung cancer: challenges and perspectives","volume":"7","author":"Cheng","year":"2014","journal-title":"Onco Targets Ther"},{"key":"10.1016\/j.crad.2021.08.001_bib14","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.lungcan.2019.04.006","article-title":"First-line afatinib for advanced EGFRm+ NSCLC: analysis of long-term responders in the LUX-Lung 3, 6, and 7 trials","volume":"133","author":"Schuler","year":"2019","journal-title":"Lung Cancer"},{"issue":"11","key":"10.1016\/j.crad.2021.08.001_bib15","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1016\/S1470-2045(17)30608-3","article-title":"Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial","volume":"18","author":"Wu","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.crad.2021.08.001_bib16","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1126\/science.267.5196.316.c","article-title":"Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in nonHodgkin\u2019s lymphoma","volume":"267","author":"Morris","year":"1995","journal-title":"Science"},{"issue":"7153","key":"10.1016\/j.crad.2021.08.001_bib17","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1038\/nature05945","article-title":"Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer","volume":"448","author":"Soda","year":"2007","journal-title":"Nature"},{"issue":"9","key":"10.1016\/j.crad.2021.08.001_bib18","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1056\/NEJMoa1704795","article-title":"Alectinib versus crizotinib in untreated ALK-positive non-small-cell lung cancer","volume":"377","author":"Peters","year":"2017","journal-title":"N Engl J Med"},{"issue":"21","key":"10.1016\/j.crad.2021.08.001_bib19","doi-asserted-by":"crossref","first-page":"2027","DOI":"10.1056\/NEJMoa1810171","article-title":"Brigatinib versus crizotinib in ALK-positive non-small-cell lung cancer","volume":"379","author":"Camidge","year":"2018","journal-title":"N Engl J Med"},{"issue":"21","key":"10.1016\/j.crad.2021.08.001_bib20","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1056\/NEJMoa2027187","article-title":"First-line lorlatinib or crizotinib in advanced ALK-positive lung cancer","volume":"383","author":"Shaw","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.crad.2021.08.001_bib21","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1007\/s10555-010-9209-4","article-title":"Biological and clinical significance of KRAS mutations in lung cancer: an oncogenic driver that contrasts with EGFR mutation","volume":"29","author":"Suda","year":"2010","journal-title":"Cancer Metastasis Rev"},{"key":"10.1016\/j.crad.2021.08.001_bib22","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.cllc.2012.09.007","article-title":"KRAS mutations in lung cancer","volume":"14","author":"Karachaliou","year":"2013","journal-title":"Clin Lung Cancer"},{"key":"10.1016\/j.crad.2021.08.001_bib23","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1016\/j.jtho.2018.07.001","article-title":"The incidence of brain metastases in stage IV ROS1-rearranged non-small cell lung cancer and rate of central nervous system progression on crizotinib","volume":"13","author":"Patil","year":"2018","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.crad.2021.08.001_bib24","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/S1470-2045(19)30690-4","article-title":"Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1-2 trials","volume":"21","author":"Drilon","year":"2020","journal-title":"Lancet Oncol"},{"issue":"7","key":"10.1016\/j.crad.2021.08.001_bib25","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1093\/annonc\/mdz131","article-title":"Crizotinib in ROS1-rearranged advanced non-small-cell lung cancer (NSCLC): updated results, including overall survival, from PROFILE 1001","volume":"30","author":"Shaw","year":"2019","journal-title":"Ann Oncol"},{"issue":"23","key":"10.1016\/j.crad.2021.08.001_bib26","doi-asserted-by":"crossref","first-page":"2613","DOI":"10.1200\/JCO.2016.71.3701","article-title":"Open-label, multicenter, phase II study of ceritinib in patients with non-small-cell lung cancer harboring ROS1 rearrangement","volume":"35","author":"Lim","year":"2017","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.crad.2021.08.001_bib27","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1016\/S1470-2045(19)30655-2","article-title":"Lorlatinib in advanced ROS1-positive non-small-cell lung cancer: a multicentre, open-label, single-arm, phase 1\u20132 trial","volume":"20","author":"Shaw","year":"2019","journal-title":"Lancet Oncol"},{"issue":"4","key":"10.1016\/j.crad.2021.08.001_bib28","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1158\/2159-8290.CD-16-1237","article-title":"Safety and antitumour activity of the multitargeted pan-TRK, ROS1, and ALK inhibitor entrectinib: combined results from two phase I trials (ALKA-372-001 and STARTRK-1)","volume":"7","author":"Drilon","year":"2017","journal-title":"Cancer Discov"},{"issue":"6","key":"10.1016\/j.crad.2021.08.001_bib29","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1007\/s00280-013-2298-3","article-title":"The VEGF pathway in lung cancer","volume":"72","author":"Alevizakos","year":"2013","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.crad.2021.08.001_bib30","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1258\/ebm.2009.009191","article-title":"Antiangiogenic therapy in lung cancer: focus on vascular endothelial growth factor pathway","volume":"235","author":"Korpanty","year":"2010","journal-title":"Exp Biol Med (Maywood)"},{"issue":"6","key":"10.1016\/j.crad.2021.08.001_bib31","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1634\/theoncologist.12-6-713","article-title":"FDA drug approval summary: bevacizumab (Avastin) plus carboplatin and paclitaxel as first-line treatment of advanced\/metastatic recurrent nonsquamous non-small cell lung cancer","volume":"12","author":"Cohen","year":"2007","journal-title":"Oncologist"},{"issue":"11","key":"10.1016\/j.crad.2021.08.001_bib32","doi-asserted-by":"crossref","first-page":"2184","DOI":"10.1200\/JCO.2004.11.022","article-title":"Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer","volume":"22","author":"Johnson","year":"2004","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.crad.2021.08.001_bib33","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1200\/JCO.2009.23.7537","article-title":"Phase I pharmacological and biological study of ramucirumab (IMC-1121B), a fully human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2","volume":"28","author":"Spratlin","year":"2010","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.crad.2021.08.001_bib34","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1097\/RTI.0000000000000116","article-title":"Correlation between EGFR mutation status and computed tomography features in patients with advanced pulmonary adenocarcinoma","volume":"29","author":"Hsu","year":"2014","journal-title":"J Thorac Imag"},{"issue":"1","key":"10.1016\/j.crad.2021.08.001_bib35","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1148\/radiol.14140848","article-title":"Advanced adenocarcinoma of the lung: comparison of CT characteristics of patients with anaplastic lymphoma kinase gene rearrangement and those with epidermal growth factor receptor mutation","volume":"275","author":"Choi","year":"2015","journal-title":"Radiology"},{"issue":"8","key":"10.1016\/j.crad.2021.08.001_bib36","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0161081","article-title":"Imaging characteristics of driver mutations in EGFR, KRAS, and ALK among treatment-na\u00efve patients with advanced lung adenocarcinoma","volume":"11","author":"Park","year":"2016","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/j.crad.2021.08.001_bib37","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.lungcan.2015.09.018","article-title":"From genotype to phenotype: are there imaging characteristics associated with lung adenocarcinomas harboring RET and ROS1 rearrangements?","volume":"90","author":"Plodkowski","year":"2015","journal-title":"Lung Cancer"},{"issue":"2","key":"10.1016\/j.crad.2021.08.001_bib38","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.cllc.2019.10.006","article-title":"Computed tomography imaging features and distribution of metastases in ROS1-rearranged non-small-cell lung cancer","volume":"21","author":"Digumarthy","year":"2020","journal-title":"Clin Lung Cancer"},{"key":"10.1016\/j.crad.2021.08.001_bib39","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.lungcan.2019.01.007","article-title":"Imaging characteristics of BRAF-mutant non-small cell lung cancer by functional class","volume":"129","author":"Mendoza","year":"2019","journal-title":"Lung Cancer"},{"issue":"2","key":"10.1016\/j.crad.2021.08.001_bib40","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1056\/NEJMoa1713137","article-title":"Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer","volume":"378","author":"Soria","year":"2018","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.crad.2021.08.001_bib41","doi-asserted-by":"crossref","first-page":"2070","DOI":"10.1073\/pnas.0709662105","article-title":"The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP","volume":"105","author":"Yun","year":"2008","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"10.1016\/j.crad.2021.08.001_bib42","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.jtho.2019.11.005","article-title":"The evolving landscape of resistance to osimertinib","volume":"15","author":"Schoenfeld","year":"2020","journal-title":"J Thorac Oncol"},{"issue":"18","key":"10.1016\/j.crad.2021.08.001_bib43","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1056\/NEJMoa1411817","article-title":"AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer","volume":"372","author":"J\u00e4nne","year":"2015","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.crad.2021.08.001_bib44","doi-asserted-by":"crossref","first-page":"2240","DOI":"10.1158\/1078-0432.CCR-12-2246","article-title":"Analysis of tumour specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers","volume":"19","author":"Yu","year":"2013","journal-title":"Clin Cancer Res"},{"issue":"3","key":"10.1016\/j.crad.2021.08.001_bib45","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","article-title":"New guidelines to evaluate the response to treatment in solid tumours. European organization for research and treatment of cancer, national cancer institute of the United States, national cancer institute of Canada","volume":"92","author":"Therasse","year":"2000","journal-title":"J Natl Cancer Inst"},{"issue":"2","key":"10.1016\/j.crad.2021.08.001_bib46","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.crad.2021.08.001_bib47","doi-asserted-by":"crossref","first-page":"4442","DOI":"10.1200\/JCO.2004.07.960","article-title":"Phase II studies of modern drugs directed against new targets: if you are fazed, too, then resist RECIST","volume":"22","author":"Ratain","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.crad.2021.08.001_bib48","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1200\/JCO.2009.25.8574","article-title":"Living with imperfection","volume":"28","author":"Mok","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.crad.2021.08.001_bib49","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1093\/annonc\/mdq587","article-title":"Bevacizumab increases the risk of arterial ischemia: a large study in cancer patients with a focus on different subgroup outcomes","volume":"22","author":"Schutz","year":"2011","journal-title":"Ann Oncol"},{"key":"10.1016\/j.crad.2021.08.001_bib50","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1001\/jamaoncol.2015.4921","article-title":"First-line erlotinib therapy until and beyond response evaluation criteria in solid tumours progression in Asian patients with epidermal growth factor receptor mutation-positive non-small-cell lung cancer: the ASPIRATION study","volume":"2","author":"Park","year":"2016","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.crad.2021.08.001_bib51","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.lungcan.2012.11.007","article-title":"Radiographic assessment and therapeutic decisions at RECIST progression in EGFR-mutant NSCLC treated with EGFR tyrosine kinase inhibitors","volume":"79","author":"Nishino","year":"2013","journal-title":"Lung Cancer"},{"issue":"11","key":"10.1016\/j.crad.2021.08.001_bib52","doi-asserted-by":"crossref","first-page":"1722","DOI":"10.1097\/JTO.0b013e31826913f7","article-title":"Epidermal growth factor receptor tyrosine kinase inhibitors beyond progressive disease: a retrospective analysis for Japanese patients with activating EGFR mutations","volume":"7","author":"Nishie","year":"2012","journal-title":"J Thorac Oncol"},{"issue":"15","key":"10.1016\/j.crad.2021.08.001_bib53","doi-asserted-by":"crossref","first-page":"2570","DOI":"10.1002\/cncr.29397","article-title":"Delay of treatment change after objective progression on first-line erlotinib in epidermal growth factor receptor-mutant lung cancer","volume":"121","author":"Lo","year":"2015","journal-title":"Cancer"},{"issue":"19","key":"10.1016\/j.crad.2021.08.001_bib54","doi-asserted-by":"crossref","first-page":"6298","DOI":"10.1158\/1078-0432.CCR-11-1468","article-title":"Disease flare after tyrosine kinase inhibitor discontinuation in patients with EGFR-mutant lung cancer and acquired resistance to erlotinib or gefitinib: implications for clinical trial design","volume":"17","author":"Chaft","year":"2011","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.crad.2021.08.001_bib55","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.ejca.2011.10.033","article-title":"A phase II study of (1)(8)F-fluorodeoxyglucose PET-CT in non-small cell lung cancer patients receiving erlotinib (Tarceva); objective and symptomatic responses at 6 and 12 weeks","volume":"48","author":"O\u2019Brien","year":"2012","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.crad.2021.08.001_bib56","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1093\/annonc\/mdq391","article-title":"First-line erlotinib and bevacizumab in patients with locally advanced and\/or metastatic non-small-cell lung cancer: a phase II study including molecular imaging","volume":"22","author":"Dingemans","year":"2011","journal-title":"Ann Oncol"},{"key":"10.1016\/j.crad.2021.08.001_bib57","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0053081","article-title":"Prognostic impact of [18F]fluorothymidine and [18F]fluoro-D-glucose baseline uptakes in patients with lung cancer treated first-line with erlotinib","volume":"8","author":"Scheffler","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.crad.2021.08.001_bib58","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1200\/JCO.2008.16.2545","article-title":"Tumour cavitation: impact on objective response evaluation in trials of angiogenesis inhibitors in non-small-cell lung cancer","volume":"27","author":"Crabb","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.crad.2021.08.001_bib59","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1102\/1470-7330.2012.0027","article-title":"Tumoural cavitation in patients with non-small-cell lung cancer treated with antiangiogenic therapy using bevacizumab","volume":"12","author":"Nishino","year":"2012","journal-title":"Cancer Imaging"},{"issue":"1","key":"10.1016\/j.crad.2021.08.001_bib60","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1097\/RTI.0000000000000451","article-title":"Imaging of novel oncological treatments in lung cancer part 1: systemic therapies","volume":"35","author":"Halpenny","year":"2020","journal-title":"J Thorac Imag"},{"issue":"1","key":"10.1016\/j.crad.2021.08.001_bib61","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1148\/radiol.10092129","article-title":"CT findings of chemotherapy-induced toxicity: what radiologists need to know about the clinical and radiological manifestations of chemotherapy toxicity","volume":"258","author":"Torrisi","year":"2011","journal-title":"Radiology"},{"key":"10.1016\/j.crad.2021.08.001_bib62","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/1470-7330-14-26","article-title":"New targeted molecular therapies for cancer: radiological response in intrathoracic malignancies and cardiopulmonary toxicity: what the radiologist needs to know","volume":"14","author":"Souza","year":"2014","journal-title":"Cancer Imaging"},{"key":"10.1016\/j.crad.2021.08.001_bib63","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1007\/s00280-011-1737-2","article-title":"Drug-induced interstitial lung disease in tyrosine kinase inhibitor therapy for non-small cell lung cancer: a review on current insight","volume":"68","author":"Min","year":"2011","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.crad.2021.08.001_bib64","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1016\/j.jtho.2016.11.2236","article-title":"Risk of treatment-related toxicities from EGFR tyrosine kinase inhibitors: a metaanalysis of clinical trials of gefitinib, erlotinib, and afatinib in advanced EGFR-mutated non-small cell lung cancer","volume":"12","author":"Ding","year":"2017","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.crad.2021.08.001_bib65","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1164\/rccm.200710-1501OC","article-title":"Interstitial lung disease in Japanese patients with lung cancer: a cohort and nested case\u2013control study","volume":"177","author":"Kudoh","year":"2008","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.crad.2021.08.001_bib66","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/S0140-6736(03)12190-3","article-title":"Severe acute interstitial pneumonia and gefitinib","volume":"361","author":"Inoue","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.crad.2021.08.001_bib67","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1164\/rccm.201308-1483ST","article-title":"An official American Thoracic Society\/European Respiratory Society statement: update of the international multidisciplinary classification of the idiopathic interstitial pneumonias","volume":"188","author":"Travis","year":"2013","journal-title":"Am J Respir Crit Care Med"},{"issue":"2","key":"10.1016\/j.crad.2021.08.001_bib68","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.lungcan.2014.12.010","article-title":"Management of crizotinib therapy for ALK-rearranged non-small cell lung carcinoma: an expert consensus","volume":"87","author":"Cappuzzo","year":"2015","journal-title":"Lung Cancer"},{"key":"10.1016\/j.crad.2021.08.001_bib69","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1186\/1471-2407-13-207","article-title":"Early pneumothorax as a feature of response to crizotinib therapy in a patient with ALK-rearranged lung adenocarcinoma","volume":"13","author":"Gennatas","year":"2013","journal-title":"BMC Cancer"},{"key":"10.1016\/j.crad.2021.08.001_bib70","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1093\/jnci\/djm086","article-title":"Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab","volume":"99","author":"Scappaticci","year":"2007","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.crad.2021.08.001_bib71","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1200\/JCO.2009.24.7353","article-title":"Tracheoesophageal fistula formation in patients with lung cancer treated with chemoradiation and bevacizumab","volume":"28","author":"Spigel","year":"2010","journal-title":"J Clin Oncol"}],"container-title":["Clinical Radiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0009926021003883?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0009926021003883?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,14]],"date-time":"2025-09-14T16:46:00Z","timestamp":1757868360000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0009926021003883"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1]]},"references-count":71,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,1]]}},"alternative-id":["S0009926021003883"],"URL":"https:\/\/doi.org\/10.1016\/j.crad.2021.08.001","relation":{},"ISSN":["0009-9260"],"issn-type":[{"type":"print","value":"0009-9260"}],"subject":[],"published":{"date-parts":[[2022,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Post-chemotherapy and targeted therapy imaging of the chest in lung cancer","name":"articletitle","label":"Article Title"},{"value":"Clinical Radiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.crad.2021.08.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Published by Elsevier Ltd on behalf of The Royal College of Radiologists.","name":"copyright","label":"Copyright"}]}}